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Key Points 51 
 52 
Question: Is the amount of gluten intake in the first 5 years associated with the risk of celiac 53 
disease autoimmunity and celiac disease in at-risk children?  54 
Findings: In this multinational prospective birth cohort consisting of 6,605 genetically 55 
predisposed children, higher gluten intake was associated with a statistically significant 56 
increase of celiac disease autoimmunity (HR 1.30, 95% CI 1.22-1.38) and celiac disease (HR 57 
1.50, 95% CI 1.35-1.66), for every gram increase of gluten intake per day.  58 
Meaning: Increased intake of gluten during the first 5 years of life was an independent risk 59 

















Importance: High gluten intake during childhood may confer risk of celiac disease. 75 
Objectives: To investigate if the amount of gluten intake is associated with celiac disease 76 
autoimmunity and celiac disease in genetically at risk children. 77 
Design, Setting, and Participants: The Environmental Determinants of Diabetes in the 78 
Young (TEDDY), a prospective observational birth cohort designed to identify environmental 79 
triggers of type 1 diabetes and celiac disease. Participants were followed at six clinical centers 80 
in Finland, Germany, Sweden and the US. Between 2004 and 2010, 8,676 newborns carrying 81 
HLA-genotypes associated with type 1 diabetes and celiac disease, were enrolled into a 82 
longitudinal observational study. In 6,757 children, screening for celiac disease with tissue 83 
transglutaminase (tTG) autoantibodies was performed annually from age 2 years. Data on 84 
gluten intake were available in 6,605 (98%) children. 85 
Exposure: Gluten intake was estimated from 3-day food records collected at 6, 9, and 12 86 
months and biannually thereafter until age 5 years. 87 
Main Outcomes: The primary endpoint was celiac disease autoimmunity, defined as positive 88 
tTG autoantibodies in two consecutive serum samples. The secondary endpoint was celiac 89 
disease confirmed by intestinal biopsy or persistently high tTG autoantibody levels.  90 
Results: Of the 6,605 children (49% females, median follow-up 9.0 years [interquartile range 91 
8.0 to 10.0 years]), 1,216 (18%) developed celiac disease autoimmunity and 447 (7%) 92 
developed celiac disease by September 30, 2017. The incidence for both endpoints peaked at 93 
age 2 to 3 years. Daily gluten intake was associated with higher risk of celiac disease 94 
autoimmunity (HR 1.30, 95% CI 1.22-1.38) and celiac disease (HR 1.50, 95% CI 1.35-1.66) 95 
for every 1-gram/day increase. The absolute risk increases corresponding to HR were 6.1% 96 
for celiac disease autoimmunity and 7.2% for celiac disease, respectively.  97 
Conclusions and Relevance: Higher gluten intake in the first 5 years was associated with 98 
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increased risk of celiac disease autoimmunity and celiac disease among genetically 99 

























Gluten is a food antigen found in wheat, rye and barley. It has a high content of proteins rich 123 
in gliadin peptides, which are resistant to complete digestion by gastrointestinal enzymes, and 124 
may cause an inflammatory response leading to celiac disease in genetically predisposed 125 
individuals
1
. Celiac disease is an autoimmune enteropathy affecting approximately 1% of the 126 
western population and attributable to both genetic and environmental factors
2
. While gluten 127 
consumption and certain human leukocyte antigen (HLA) genes are key factors for celiac 128 
disease development, not all individuals with a predisposing genetic background develop 129 
lifelong intolerance to gluten
3
, and the risk is likely to be modified by the timing or quantities 130 
of gluten consumed as well as other potential pathophysiologic factors
4,5
.  131 
Celiac disease commonly presents early in childhood
6
, highlighting the importance of 132 
studying early life events for identifying triggers of the disease
7
. It was initially reported that 133 
early or late introduction of gluten to infants increased the risk of celiac disease
8,9
. The timing 134 
of infant gluten exposure has not been consistently associated with celiac disease risk
10,11
, and 135 
this has led to changing recommendations for infant feeding
12
. Importantly, it remains unclear 136 
whether the amount of gluten consumed triggers celiac disease
11,13-15.  
137 
Gluten intake during the first 5 years of life was assessed from genetically at-risk children 138 
followed in the multinational prospective birth cohort the Environmental Determinants of 139 
Diabetes in the Young (TEDDY) study. The aim was to investigate whether the amount of 140 
gluten in the diet was associated with development of celiac disease autoimmunity and celiac 141 
disease, to allow better understanding of the pathogenesis and to inform feeding 142 






Study population 147 
This prospective cohort study follows children from birth up to 15 years of age at clinical 148 
research centers in Colorado, Georgia, Florida, and Washington state in the U.S., as well as 149 
Finland, Germany, and Sweden
16
. The final date of follow-up for the present study was 150 
September 30, 2017. 151 
The primary goal was to identify genetic and environmental factors associated with increased 152 
risk of type 1 diabetes, celiac disease, or both. Newborn infants were screened for HLA 153 
genotypes associated with type 1 diabetes and celiac disease
17
. Distribution of the HLA-154 
genotypes in the study is shown in Table 1. For all study participants separate written 155 
informed consents for genetic screening and participation in the prospective follow-up 156 
beginning at birth were obtained from a parent or primary caretaker. Local institutional or 157 
regional ethics review boards in all participating countries approved the study. Full details of 158 
study design, eligibility and methods have been published previously
16,18-20
. 159 
  160 
Dietary assessment  161 
Gluten intake was estimated from 3-day food records collected at ages 6, 9, and 12 months 162 
and biannually (i.e. at 18, 24, 30, 36 months) thereafter until 5 years of age. Parents were 163 
asked to keep a food record documenting all foods and drinks consumed by the child over the 164 
3-day periods (2 weekdays and 1 weekend day) before the scheduled clinic visit. Normal food 165 
habits were encouraged during the time of food record collection. Portion sizes were 166 
estimated using household measurements, food models, pictures, drawings and shapes of 167 
foods as references. A specific booklet was developed and used in all countries to facilitate 168 
estimation of food portion sizes. The dietary assessment method used in the study has been 169 
described in detail elsewhere
15,21
.  170 
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Dietary intake was analyzed using the food composition databases from each participating 171 
country. For analyses at the food group level, a harmonized food grouping system was 172 
developed with comparable food groups and quantification of food intakes between the 173 
databases used in individual countries
22
. Composite foods and recipes were broken down to 174 
ingredients. Mean intake (g/day) was calculated from total intake of gluten-containing flours 175 
(wheat, rye, and barley) reported in the 3-day recording period. Vegetable protein content 176 
(using country-specific values) was obtained from the daily intake of gluten-containing flours 177 
and converted to amount of gluten using a conversion factor of 0.8 (gluten content in wheat 178 
protein)
23
. The converted amount was analyzed as absolute gluten intake (g/day).  179 
 180 
Measurement of tissue transglutaminase (tTG) autoantibodies 181 
Testing for serum tTG autoantibodies started from the 24 months clinic visit and continued 182 
yearly thereafter. Radiobinding assays were used to measure tTG autoantibody levels in two 183 
laboratories as previously described
19
. Briefly, samples from US centers were screened for 184 
IgA-tTG autoantibodies at the Barbara Davis Center for Childhood Diabetes, University of 185 
Colorado (Denver laboratory)
24
. Samples from European centers were tested at the University 186 
of Bristol, UK, (Bristol laboratory), using an assay that detected both IgA and IgG 187 
autoantibodies against tTG
25
. To harmonize results, all samples with tTG autoantibody index 188 
>0.01 in the Denver laboratory were sent for quantification of tTG autoantibodies in the 189 
Bristol laboratory, the reference laboratory for the study
19
. Results were expressed in arbitrary 190 
units derived from a standard curve consisting of dilutions of serum taken from a patient with 191 
celiac disease. If a sample tested positive from the Bristol laboratory (≥1.3 units)
25
, the child’s 192 
earlier blood samples were retrospectively analyzed in the Bristol laboratory to determine the 193 
age at which tTG autoantibodies first became detectable. Persistence of tTG autoantibodies 194 
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was confirmed by finding positive results in two consecutive samples at least 3 months 195 
apart
26
.  196 
Outcomes 197 
The primary outcome was celiac disease autoimmunity, defined as positive tTG 198 
autoantibodies measured in the Bristol laboratory in two consecutive samples. Children 199 
meeting the criteria for persistence of tTG autoantibodies were referred to a gastroenterologist 200 
at the clinical discretion of their usual physician. The decision whether to perform a biopsy 201 
was not determined by the TEDDY study protocol. The secondary endpoint was celiac 202 
disease, which was defined as an intestinal biopsy showing a Marsh score ≥2 or, if biopsy was 203 
not performed, non-biopsy proven celiac disease was defined by the average of two samples 204 
≥100 units
26
.  205 
 206 
Statistical analyses  207 
Time to event was defined as the age of the first positive tTG autoantibody sample for 208 
children who later fulfilled the criteria for both celiac disease autoimmunity and celiac 209 
disease. The right censored time for celiac disease autoimmunity was the age at the last 210 
negative tTG autoantibody sample and for celiac disease was the age at the last clinic visit at 211 
which celiac disease had not been diagnosed. In order to control for differences in age or body 212 
size, we analyzed energy and age adjusted intake using the residual method
27
, as well as 213 
intake per 10 kg bodyweight at a given age, in addition to absolute daily intake.  214 
To address concerns regarding missing data and variability in dietary data, joint modeling was 215 
selected as the pre-specified analysis, chosen to assess the association between gluten intake 216 
over time and the risk of celiac disease autoimmunity and celiac disease
28,29
. Joint modeling 217 
assesses the association by fitting an individual trajectory for the intake over time. Based on 218 
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the patterns seen in eFigure 1 and eFigure 2, a linear trajectory was assumed for the 219 
longitudinal model and the incidence peak in the beginning was considered for the baseline 220 
hazard estimation assuming piecewise constant. Seven intervals without weighting were 221 
applied per the best model fit based on ∆AIC
30
. The longitudinal model was adjusted for 222 
energy intake (kcal/day) at the same time, and the time to event model was adjusted for HLA-223 
genotype, sex, country of residence and family history (mother, father, or sibling) of celiac 224 
disease. SAS macro JMFit was used for the analyses
31
. From the log-hazard model fitted by 225 
joint modeling, absolute risk by 3 years old was estimated as the cumulative hazard, in 226 
relation to the average daily gluten intake at 2 years of age. The hazard ratios and absolute 227 
risk increases were assessed at 1 unit increase of gluten intake, conditioned on energy intake 228 
(kcal/day) at the same time, HLA-genotype, sex, country of residence and family history of 229 
celiac disease. 230 
In addition, two Cox regression analyses including the most recent intake prior to the event 231 
and energy intake at the same time as time dependent covariates were performed as sensitivity 232 
analyses: 1) all children, and 2) children with gluten intake available within 1 year prior to 233 
each risk-set, to control for various lag times between gluten exposure and the event. 234 
 235 
As a post-hoc analysis, we examined the effects of age-specific gluten intake. The association 236 
with subsequent incidence of celiac disease autoimmunity and celiac disease was assessed 237 
using Cox regression, focusing on absolute intake reported at the age of each TEDDY visit. 238 
For children whose gluten intake at the specific age was the most recent data prior to the 239 
event, the standard Cox regression model assessed the effects of gluten intake reported at the 240 
specific age as a time constant covariate. For children who had additional gluten intake data 241 
available after the specific age, the most recent gluten intake prior to the event needs to be 242 
controlled to assess the effects of the intake reported at the specific age (i.e., the primary 243 
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interest). In order to assess the effects of age-specific gluten intake in addition to the effect of 244 
current intake, the model considered the most recent intake prior to the event as a time 245 
dependent covariate and the intake at the specific age as a time constant covariate. 246 
The proportional hazard assumption was examined using martingale residual analysis with the 247 
supremum test. The functional form in the martingale residual plot, as well as change-point 248 
analysis based on log-rank test
32
, suggested a dichotomization for absolute gluten intake at 2 249 
years of age. 250 
Two-sided p-values are reported. Statistical significance was determined when the p-value 251 
was <0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., 252 
Cary, NC). 253 
 254 
Results 255 
Between September 2004 and February 2010, 424,788 newborn infants were screened for 256 
HLA and 21,589 (5%) HLA-eligible infants were identified, of whom 8,676 (40%) were 257 
enrolled in this study before the age of 4 months. The most common reasons for failing to 258 
enroll to this 15-year follow-up study were related to protocol characteristics (e.g. blood draw, 259 
demanding protocol) or family circumstances (e.g. changing contact information)
33
. At time 260 
of analysis, 6,757 children had been screened for tTG autoantibodies, and 6,605 (97.8%) had 261 
submitted at least one 3-day food record during the first 5 years of life or prior to detection of 262 
tTG autoantibody positivity (eFigure 3). Descriptive characteristics of the study population 263 
are presented in Table 1. Of 6,605 children in the study, 3,233 (49%) were girls. Data on 264 
gluten intake were missing or of inadequate quality in 4,465 visits (8%) of the 52,952 visits 265 
for which parallel tTG results were available. In total, 204 (3%) subjects completed at only 266 
one food record. Among children with celiac disease autoimmunity, 20 (1.6%) subjects 267 
completed one food record more than 3 months prior to their seroconversion.  268 
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As of September 30, 2017, among the 6,605 children included in the analysis, 1,411 (21%) 269 
had tested positive for tTG autoantibodies on at least one occasion. During a median follow 270 
up of 9.0 years (range 1.0 – 13.0, interquartile range 8.0 – 10.0) 1,216 (18%) children with 271 
celiac disease autoimmunity had seroconverted to positive tTGA autoantibodies at a median 272 
age of 3.3 years (range 0.9 - 11.5), and 447 (7%) children fulfilling the criteria for celiac 273 
disease had their seroconversion at a median age of 3.0 years (range 0.9 – 11.2). The 274 
incidence of seroconversion for both endpoints peaked around 2 to 3 years of age (eFigure 1).   275 
Children homozygous for DR3-DQ2 were at the highest risk of celiac disease autoimmunity 276 
and celiac disease. Swedish residence, female sex, and family history of celiac disease were 277 
also associated with increased risk for both endpoints (eTable 1).  278 
Gluten consumption linearly increased with age with some national differences (eFigure 2, 279 
eTable 2). Higher intake of gluten during the first 5 years of life was associated with 280 
increased risk of both celiac disease autoimmunity and celiac disease (Table 2). Absolute 281 
intake of gluten was associated with higher risk of celiac disease autoimmunity (HR 1.30, 282 
95% CI 1.22 -1.38; p= <0.001) and celiac disease (HR 1.50, 95% CI 1.35 -1.66; p= <0.001) 283 
for every per 1-gram/day increase in gluten consumption. Age- and energy adjusted gluten 284 
intake was associated with higher risk of celiac disease autoimmunity (HR 1.40, 95% CI 1.30 285 
-1.52; p= <0.001) and celiac disease (HR 1.43, 95% CI 1.23 -1.68; p= <0.001) for every per 286 
1-gram/day increase in gluten consumption. In addition, gluten intake per 10 kg bodyweight 287 
was associated with higher risk of celiac disease autoimmunity (HR 1.87, 95% CI 1.66 -2.11; 288 
p= <0.001) and celiac disease (HR 2.18, 95% CI 1.75 -2.71; p= <0.001) for every per 1-289 
gram/day/10kg increase in gluten consumption. Sensitivity analysis using Cox regression 290 
models supported the statistical significance found from the joint modeling analysis (Table 291 
2).  292 
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In the country-specific analyses, a higher gluten intake was associated with an increased risk 293 
of celiac disease autoimmunity in all countries (eTable 3). Absolute gluten intake and age- 294 
and energy adjusted intake were associated with increased risk for celiac disease in the U.S. 295 
and Sweden.  296 
Finally, the absolute risks by 3 years of age in relation to the average daily gluten intake at 2 297 
years of age were assessed. The absolute risk difference suggests the risk increase if gluten 298 
was 1 unit higher than the average daily gluten intake at 2 years of age. The absolute risk 299 
increases were 6 to 18% for celiac disease autoimmunity and 3 to 20% celiac disease, 300 
respectively (Table 3). 301 
Post-hoc analysis 302 
In view of the early peak incidence of seroconversion to later celiac disease autoimmunity and 303 
celiac disease, we focused on the intake reported at 2 and 3 years of age, respectively. Gluten 304 
intake reported at the 2-year visit was available for 833 children with celiac disease 305 
autoimmunity and intake reported at the 3-year visit was available for 526 children with celiac 306 
disease autoimmunity. The analysis showed that gluten intake at 2 years of age had an 307 
independent effect on the risk of celiac disease autoimmunity and celiac disease, in addition to 308 
the current intake during the first 5 years of life (eTable 4).  309 
The supremum test showed no indication of violating the proportional hazard assumption, but 310 
there was a deviation at >2g gluten intake per day in the martingale residual plot (eFigure 4). 311 
In addition, the change point analysis showed a significance risk difference between >2 and ≤ 312 
2g/day. Based on these analyses, we dichotomized the gluten intake reported at 2 years as >2 313 
and ≤2 g/day and examined the adjusted HRs with the endpoints (Table 4). Children who 314 
consumed gluten >2g/day at 2 years of age had a 50% higher risk of celiac disease 315 
autoimmunity (HR 1.49, 95% CI 1.16 – 1.91; p= <0.002) and a 75% higher risk of celiac 316 
disease (HR 1.75, 95% CI 1.10 – 2.81; p= <0.019), compared with those who consumed ≤2g 317 
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gluten per day. When analyzing absolute gluten intake reported at the 2-year visit and risk for 318 
developing celiac disease autoimmunity and celiac disease, using a subsequent increase in 319 
gluten intake, a linear increase in hazard ratios were seen for higher intakes (Table 5). 320 
Discussion 321 
Higher gluten intake in the first 5 years was associated with increased risk of celiac disease 322 
autoimmunity and celiac disease among genetically predisposed children. 323 
The incidence of both endpoints peaked around 2 to 3 years of age. In the post-hoc analysis, 324 
the association with gluten intake on these risks was significantly increased if the child 325 
consumed more than 2 g/day at around 2 years of age, which corresponds to approximately 326 
one slice (35 g) of white bread or 1 portion of cooked pasta (150g). Also, hazard ratios 327 
increased with subsequent higher gluten intake at the 2 year visit suggesting that higher 328 
intakes were associated with higher risk of celiac disease autoimmunity and celiac disease. 329 
These findings are in line with a previous retrospective case-control study of gluten intake in 330 
Swedish children born during the mid-1980s, which showed that children subsequently 331 
diagnosed with celiac disease had been introduced to larger amounts of gluten-containing 332 
foods compared with children who did not develop celiac disease
13
.  333 
The hypothesis that gluten given in small amounts at 5 to 6 months of age would protect at-334 
risk children from developing celiac disease was furthermore addressed in a randomized 335 
placebo-controlled intervention trial, though with null results
11
. In the same study population, 336 
mean daily gluten intake, from 10 months of age when unrestricted gluten consumption was 337 
allowed, was not associated with celiac disease up to 3 years of age, except in children 338 
carrying the HLA-genotype HLA-DQ2.2/-DQ7
14
.  339 
In contrast to the randomized placebo-controlled intervention trial, gluten consumption during 340 
the first 2 years of life was previously found associated with increased risk of celiac disease in 341 
a subset of Swedish children from the present cohort, and furthermore, children in the upper 342 
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tertile of gluten intake were at a 2-fold increased risk of celiac disease, compared with 343 
children with lower gluten intake. This nested case-control study on 146 children with biopsy 344 
confirmed celiac disease and 436 matched controls indicated that the amount of gluten 345 
consumed could be a risk factor for celiac disease
15
. 346 
For the current study, food record data from all the participating countries have been 347 
harmonized which enabled us to do longitudinal analysis of the full birth cohort. In addition, 348 
we have extended the data with gluten intake up to 5 years of age and included another 301 349 
children diagnosed with celiac disease and performed time to event analyses. This extended 350 
data set yields credible power to do country-specific analysis for celiac disease autoimmunity 351 
and celiac disease, except for the German site, which had only 16 cases with celiac disease. In 352 
these country-specific analyses, a higher gluten intake was associated with an increased risk 353 
of celiac disease autoimmunity in all countries, whereas absolute gluten intake and age- and 354 
energy adjusted intake were only associated with increased risk for celiac disease in the U.S. 355 
and Sweden.  356 
Despite similar dietary assessment methods and calculation of gluten intake, discrepancies in 357 
results between the studies are likely attributed to study design and population size. In the 358 
randomized controlled study, the gluten introduction was overlooked and gluten amounts 359 
were fixed
11
, which indeed differed from the present observational study consisting of a larger 360 
population that reflected the natural variations of gluten intake in real life. Other contributing 361 
factors may be differences in exposures to various triggering environmental factors such as 362 
gastrointestinal infections or rotavirus vaccination status
5
, which partly could explain why 363 
Swedish children are more prone to develop celiac disease as compared to children from other 364 
countries.  365 
A major strength of this study as compared to the aforementioned the randomized controlled 366 
study 
11
, is its prospective study design, enrolling a large cohort of children with the same 367 
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genetic risk, from four countries with different infant feeding habits and following the same 368 
study protocol. Another strength is the dietary assessment method that allowed repeated 369 
measurements to capture changes in dietary habits in growing infants and young children over 370 
time prior to disease onset. The prospective design also reduced the effect of changes in 371 
dietary habits because parents were unaware of their child’s autoantibody status at time food 372 
records were collected. Our analyses were also adjusted for known confounders for celiac 373 
disease (HLA, country, gender, and having a family member with celiac disease)
26
. Moreover, 374 
potential confounders such as socioeconomic status in terms of maternal smoking (during 375 
pregnancy), maternal education, and maternal age had previously already been analyzed and 376 
were not associated with risk of celiac disease
34 
and therefore considered less likely to 377 
confound the results.   378 
Limitations 379 
This study has several limitations. First, the lack of information of analyzed gluten content in 380 
foods in national food composition databases. Therefore, the same conversion factor for 381 
estimation of gluten content in wheat, rye and barley was chosen because this method has 382 
been used in several previous studies
10,14,15,35
. Other studies have used cereal specific 383 
conversion factors for the estimation of gluten content
36
. Second, calculations of gluten 384 
content are approximate as they are based on self-reported dietary data. Different dietary 385 
assessment methods together with differences in methods of estimating gluten content are 386 
challenging when comparing results from previous studies. Conclusions should therefore be 387 
taken with care. A randomized trial of different amounts during early childhood in genetically 388 
at-risk individuals would therefore be warranted to confirm our findings. 389 
Conclusions 390 
Higher gluten intake in the first 5 years was associated with increased risk of celiac disease 391 
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Table 1. Descriptive characteristics of the study population, by study endpoint.   494 
 Children always negative for 
tTG autoantibodies 
(n = 5,194) 
Children with  
celiac disease autoimmunity 
(n = 1,216)  
Children with celiac 
disease 
(n = 447) 
Country n (%) n (%) n (%) 
    USA 2108 (40.5) 444 (36.5) 131 (29.3) 
    - HLA DR3-DQ2/DR3-DQ2a 391 (18.5) 194 (43.7) 69 (52.7) 
    - HLA DR3-DQ2/DR4-DQ8b 849 (40.3) 183 (41.2) 50 (38.2) 
    - HLA othersc 868 (41.2) 67 (15.1) 12 (9.1) 
    Finland 1218 (23.5) 251 (20.6) 78 (17.4) 
    - HLA DR3-DQ2/DR3-DQ2a 124 (10.2) 79 (31.5) 36 (46.2) 
    - HLA DR3-DQ2/DR4-DQ8b 376 (30.9) 120 (47.8) 30 (38.5) 
    - HLA othersc 718 (58.9) 52 (20.7) 12 (15.4) 
    Germany 314 (6.1) 57 (4.7) 16 (3.6) 
    - HLA DR3-DQ2/DR3-DQ2a 50 (15.9) 22  (38.6) 9 (56.2) 
    - HLA DR3-DQ2/DR4-DQ8b 131 (41.7) 19 (33.3) 4 (25.0) 
    - HLA othersc 133 (42.4) 16 (28.1) 3 (18.8) 
    Sweden 1554 (29.9) 464 (38.2) 222 (49.7) 
    - HLA DR3-DQ2/DR3-DQ2a 225 (14.5) 202 (43.5) 108 (48.6) 
    - HLA DR3-DQ2/DR4-DQ8b 690 (44.4) 152 (32.8) 66 (29.7) 
    - HLA othersc 639 (41.1) 110 (23.7) 48 (21.6) 
First degree relative with celiac disease    
    Yes  129 (2.5) 126 (10.4) 77 (17.2) 
    No 5065 (97.5) 1090 (89.6) 370 (82.8) 
Sex    
    Female  2453 (47.3) 693 (57.0) 281 (62.9) 
    Male 2741 (52.7) 523 (43.0) 166 (37.1) 
Breastfeeding duration, months, median (q1, q3) 7.8 (3.5, 12.0) 8.3 (5.0, 12.0) 8.1 (5.0, 12.0) 
Age at gluten introduction, months, mean (SD) 6.2 (1.9) 6.1 (1.8) 5.9 (1.9) 
22 
 
Footnote: Detailed description of human leukocyte antigen (HLA) genotypes followed in TEDDY. 495 
a DR3-DQA1*05:01-DQB1*02:01 / DR3-DQA1*05:01-DQB1*02:01 496 
b DR4-DQA1*03:0X-DQB1*03:02 / DR3-DQA1*05:01-DQB1*02:01 497 
c DR4-DQA1*03:0X-DQB1*03:02 / DR4-DQA1*03:0X-DQB1*03:02 or DR3-DQA1*05:01-DQB103:02 / DR8-DQA1*04:01-DQB1*04:02, 498 
DR4-DQA1*03-DQB1*03:02/DR3-DQA1*05:01-DQB1*02: 01, DR4-DQA1*03-DQB1*03:02/DR4-DQA1*03-DQB1*03: 02, DR4-DQA1*03-DQB1*03:02/DR8-499 
DQA1*04:01-DQB1*04: 02, DR3-DQA1*05:01-DQB1*02:01/DR3-DQA1*05:01-DQB1*02:01, DR4-DQA1*03-DQB1*03:02/DR4-DQA1*03-DQB1*02, DR4-DQA1*03-500 
DQB1*03:02/DR1-DQA1*01:01-DQB1*05:01, DR4-DQA1*03-DQB1*03:02/DR13-DQA1*01: 02-DQB1*06:04, DR4-DQA1*03-DQB1*03:02/DR9-DQA1*03-501 














Table 2. Daily gluten intake and risk for developing celiac disease autoimmunity and celiac disease in the TEDDY study.  514 
  Celiac disease autoimmunity Celiac disease 
Analysis 
a
 Measurements of gluten  HR (95% CI)  p-value  HR (95% CI)  p-value  
Joint modeling, n=1,216   Absolute intake (g/day) 1.30 (1.22 to 1.38) <0.001 1.50 (1.35 to 1.66) <0.001 
   Residual intake (g/day) b  1.40 (1.30 to 1.52) <0.001 1.43 (1.23 to 1.68) <0.001 
   Intake/10kg body weight 1.87 (1.66 to 2.11) <0.001 2.18 (1.75 to 2.71) <0.001 
Cox regression, n=1,216   Absolute intake (g/day) 1.14 (1.11 to 1.17) <0.001 1.14 (1.09 to 1.20) <0.001 
   Residual intake (g/day) b  1.12 (1.09 to 1.15) <0.001 1.07 (1.02 to 1.13) 0.011 
   Intake/10kg body weight 1.19 (1.14 to 1.23) <0.001 1.14 (1.07 to 1.22) <0.001 
Cox regression including only 
those with gluten consumption 
available within 1 year prior 
to time of event, n=905 
  Absolute intake (g/day) 1.12 (1.08 to 1.16) <0.001 1.07 (1.02 to 1.13) 0.009 
  Residual intake (g/day) b  1.09 (1.05 to 1.13) <0.001 1.04 (0.99 to 1.10) 0.140 
  Intake/10kg body weight 1.15 (1.10 to 1.20) <0.001 1.12 (1.05 to 1.21) 0.002 
a Adjusting for HLA-type, country, sex, FDR with celiac disease, and energy intake 515 
b Age- and energy adjusted intake using the residual method (ref 27). 516 
n = Number of children with celiac disease autoimmunity included in each analysis.  517 
  518 
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Table 3. Absolute risk for developing celiac disease autoimmunity and celiac disease in the TEDDY study, conditioned on HLA-type, country, 519 
sex, FDR with celiac disease, and energy intake. Cumulative hazard from the log-hazard model fit by the joint modeling in Table 2. 520 
  Celiac disease autoimmunity Celiac disease 




Absolute risk by  





Absolute risk by 
3 years of age if  







Absolute risk by  





Absolute risk by 
3 years of age if  







Absolute intake (g/day) 3.71 28.1 34.2 6.1 20.7 27.9 7.2 
Residual intake (g/day) b 0.48 18.7 24.6 5.9 7.8 10.7 2.9 
Intake/10kg body weight 2.91 51.9 70.2 18.3 35.0 55.0 20.0 
a Average gluten intake reported at the 2-year visit was considered as reference  521 
b Age- and energy adjusted intake using the residual method (ref 27). 522 
Abbreviation: FDR; First degree relative 523 
  524 
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Table 4. Daily absolute gluten intake reported at the 2-year visit and risk for developing celiac disease autoimmunity and celiac disease 525 
in the TEDDY study.  526 
  Celiac disease autoimmunity Celiac disease 
Model  HR (95% CI) p-value HR (95% CI) p-value 
 A ≤ 2g/day 1  1  
 >2 g/day 1.49 (1.16 to 1.91) 0.002 1.75 (1.10 to 2.81) 0.019 
 B ≤ 2g/day 1  1  
 >2 g/day 1.62 (1.29 to 2.03) <0.001 1.71 (1.12 to 2.60) 0.012 
A: Adjusted for HLA-type, country, sex, FDR with celiac disease, and energy intake and the most recent gluten intake prior to the event as time dependent covariates 527 
B: Adjusted for HLA-type, country, sex, FDR with celiac disease, and energy intake at 2 year TEDDY visit. 528 
  529 
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Table 5. Daily absolute gluten intake reported at the 2-year visit and risk for developing celiac disease autoimmunity and celiac disease 530 
in the TEDDY study. 531 
  Celiac disease autoimmunity Celiac disease 
Model
a
  HR (95% CI) p-value HR (95% CI) p-value 
 ≤ 2 g/day  1  1  
 > 2 and ≤ 4 g/day 1.52 (1.20 to 1.93) <0.001 1.57 (1.02 to 2.41) 0.041 
 > 4 and ≤ 6 g/day 1.77 (1.37 to 2.29) <0.001 1.96 (1.24 to 3.11) 0.004 
 > 6 and ≤ 8 g/day 2.43 (1.76 to 3.36) <0.001 2.69 (1.53 to 4.71) <0.001 
 > 8 g/day 1.54 (0.81 to 2.93) 0.70 2.04 (0.68 to 6.08) 0.20 
aAdjusted for HLA-type, country, sex, FDR with celiac disease, and energy intake at 2 year TEDDY visit 532 
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